Remove Antibody Remove Clinical Trials Remove Immune Response Remove Trials
article thumbnail

Intranasal delivery of AstraZeneca COVID-19 vaccine fails to generate strong immune response

BioPharma Reporter

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

article thumbnail

Adjuvanted Covid-19 vaccine elicits stronger immune response

Drug Discovery World

Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The researchers found that the immune response induced by two doses of GBP510/AS03 was superior to that induced by ChAdOx1-S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clinical Trials for Celiac Disease: Insights from Beyond Celiac’s Kate Avery

XTalks

A blood test can detect antibodies to gluten, but a definitive diagnosis requires a biopsy of the small intestine. However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. How does Beyond Celiac spread awareness about research and clinical trials for celiac disease?

article thumbnail

Temperature-stable tuberculosis vaccine safe, prompts immune response in first-in-human trial

Medical Xpress

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. Results are published in Nature Communications.

article thumbnail

Antibody therapy shows anti-tumour activity in advanced cancer

Drug Discovery World

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells.

Antibody 115
article thumbnail

Promising first clinical trial data for new rabies vaccine candidate

Drug Discovery World

Researchers from the University of Oxford have today reported new findings from a Phase I clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG. No serious adverse events or safety concerns were reported during the trial.

article thumbnail

China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma

Pharmaceutical Technology

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).